Business
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response in the first eight patients evaluated Results ...
About this update from Bioinvent International Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response in the first eight patients evaluated","length":241,"tagName":"p"}]},{"val":[{"type":"text","content":"Results equate to an objective response rate (CRs and PRs) of 63%","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Data from an earlier cutoff date in February are included in an abstract published today by the European Hematology Association (EHA) 2025 conference","length":149,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":455,"olType":false},{"type":"text","content":"LUND, SE / ACCESS Newswire / May 14, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces latest updated data from the ongoing Phase 2a study of BI-1206 in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL). Additionally today, an abstract containing data from an earlier February cutoff date has been published by the European Hematology Association (EHA) as part of its 2025 congress due to take place June 12-15 in Milan, Italy.","length":680,"tagName":"p"},{"type":"text","content":"The data released today show the first eight patients in the triple combination arm of BioInvent's ongoing Phase 2a in non-Hodgkin's lymphoma. All patients exhibited disease control at first assessment (DCR 100%), and results show an overall objective response rate of 63% with two patients achieving a complete response (CR) and three patients with partial responses (PR). Stable disease (SD) was observed in the three remaining patients. The combination has been well tolerated in all patients treated at the cut-off-date. These data are further updated compared to the data included in the EHA abstract.","length":614,"tagName":"p"},{"type":"text","content":""We continue to be encouraged by the early data demonstrating robust clinical activity and manageable safety profile in the ongoing triple combination arm of the Phase 2a study of BI-1206 in combination with rituximab ...